PDF电子书：Synthetic Messenger RNA and Cell Metabolism Modulation (Springer MMB-

xyklmu

) m% k0 z/ D) Y. T, D' j6 A  X! q+ S, B4 o, f
[hide][/hide]8 H6 ?3 ]3 O$ y: O6 |
: ~$ D' Z- B2 I8 r: s0 c1 z

5 }" @4 v0 I9 @- b5 H& P3 gSynthetic Messenger RNA; k7 {( a/ w% k, f4 n# U
and Cell Metabolism Modulation
" w4 V; @4 q6 ~9 cMethods and Protocols
) y. P% m( E' S# ^Edited by
8 M/ m6 j6 j# U  VPeter M. Rabinovich( i/ z' {  `1 L1 p2 s. y5 t) T
Department of Genetics, The Anlyan Center, Yale School of Medicine,
. Y- W5 a' G4 ], p9 nNew Haven, Connecticut, USA* |- [: ~- \- H

' D' }3 H+ }  ^, B1 s( o, {) \8 F/ p( G8 y0 F, x$ Y! a% h4 X& V
Contents
/ z8 F2 `) Q/ o9 S# NPreface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
9 f# V* d" v4 X- Y# FContributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
% ?% l0 i/ S$ ?: [' S0 P: E: rPART I mRNA SYNTHESIS, PURI FI CATION, AND TRANSFER# l9 V4 Y8 F' d4 P: }3 R1 M0 A
1 Cell Engineering with Synthetic Messenger RNA . . . . . . . . . . . . . . . . . . . . . . 3
- `: Q4 n' b! l1 X* e" M5 A. XPeter M. Rabinovich and Sherman M. Weissman
: L% @7 `1 w  s4 C  y8 A* P2 In Vitro Transcription of Long RNA Containing Modified Nucleosides . . . . . 29
1 _% }& d+ v+ t6 Y; PNorbert Pardi, Hiromi Muramatsu, Drew Weissman, and Katalin Karikó0 `8 Y  J: e+ H1 x% f% h/ B
3 HPLC Purification of In Vitro Transcribed Long RNA . . . . . . . . . . . . . . . . . . 43( g4 C0 O* A  s0 B4 X) j
Drew Weissman, Norbert Pardi, Hiro Muramatsu, and Katalin Karikó/ i7 b) P2 F0 N7 U0 p
4 Synthetic mRNAs with Superior Translation and Stability Properties . . . . . . . . 55' I. Q" i* Z4 q; ?& I/ X3 G3 I# @3 A
Ewa Grudzien-Nogalska, Joanna Kowalska, Wei Su, Andreas N. Kuhn,& e1 _5 q' ~" s# D8 A
Sergey V. Slepenkov, Edward Darzynkiewicz, Ugur Sahin, Jacek Jemielity,5 R7 o" l- Q. v0 k0 Y  d0 a
and Robert E. Rhoads
0 Y) x% V0 E7 n0 y1 X5 Nonviral, Cationic Lipid-Mediated Delivery of mRNA . . . . . . . . . . . . . . . . . . 73, x, N. ^+ P# ~( k
James G. Hecker7 o+ [# O7 I$ q) j( F. W
6 Light-Induced mRNA Transfection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89  Z3 o0 W# Q8 B
Sigurd Leinæs Bøe and Eivind Hovig
% Z3 u8 r2 B3 r1 q7 Engineering B Cells with mRNA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101, L8 W4 v1 e7 R1 y6 }% `
Jaewoo Lee, David Boczkowski, and Smita Nair& {1 ~& j5 R- x, o
8 Programming Human Dendritic Cells with mRNA . . . . . . . . . . . . . . . . . . . . . 111" `, K, F/ F- c, M5 G
Jaewoo Lee, David Boczkowski, and Smita Nair
3 E: {6 m* g: }) y3 k: @. t0 `9 Large Volume Flow Electroporation of mRNA: Clinical Scale Process . . . . . . . 1279 K$ H8 _# U) K, m% ~
Linhong Li, Cornell Allen, Rama Shivakumar, and Madhusudan V. Peshwa
# x/ n: M6 M' k# H( }10 Retrovirus-Based mRNA Transfer for Transient Cell Manipulation . . . . . . . . . 139
: o/ ~( R- T3 LMelanie Galla, Axel Schambach, and Christopher Baum: x: Z' n  C8 O+ M4 K! K2 E2 Q1 `
11 mRNA Delivery to Human Dendritic Cells by Recombinant Yeast
. P/ U8 ~9 `. a8 S% U4 S, ]and Activation of Antigen-Specific Memory T Cells. . . . . . . . . . . . . . . . . . . . . 163
6 x& d9 e  y; K, _( d/ E8 |; D  ~Frank Breinig, Tanja Breinig, and Manfred J. Schmitt, F0 N: `* A8 X% j3 c
PART II MODULATION AND MONITORING OF CELL METABOLISM& P3 j) c/ V9 G0 w+ Q% ~
12 Nonviral RNA Transfection to Transiently Modify T Cells3 N% I3 |5 [$ p7 p* ^
with Chimeric Antigen Receptors for Adoptive Therapy . . . . . . . . . . . . . . . . . 187
" T6 K' p9 a- FTobias Riet, Astrid Holzinger, Jan Dörrie, Niels Schaft, Gerold Schuler,: @% l; \9 ~, D1 @% M
and Hinrich Abken0 w  m% i0 Q; P% l% A5 Y
13 Natural Killer Cell Reprogramming with Chimeric Immune Receptors . . . . . . 203
7 p) I# R- U6 l8 i$ a- a8 xNoriko Shimasaki and Dario Campana
9 Q' n6 w' h$ N, U) Q' h8 vviii Contents
! p) O5 y: t* p, e; k( G14 Reprogramming to Pluripotency and Differentiation of Cells" N. v0 C/ Z* q$ v" }% }
with Synthetic mRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
: \2 _6 _% Z0 O, H0 P. [Peizhe Wang and Jie Na
! k* k6 c& W8 C2 M' w) _+ o$ ~15 Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro
& g1 ~" H6 \  }$ b) Tand In Vivo Preclinical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2358 C0 s) u2 l+ c! \7 ?, p* [- f
Mustafa Diken, Sebastian Kreiter, Abderraouf Selmi, Özlem Türeci,
7 W( R$ b) i5 u6 jand Ugur Sahin2 J* ]2 G6 f0 U
16 Mannosylated and Histidylated LPR Technology for Vaccination
3 l6 S; |- H, {with Tumor Antigen mRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2476 x7 c9 Q$ v3 k7 E) p
Chantal Pichon and Patrick Midoux
' x! ~4 \7 u. r17 Analysis of Survivin-Speci fi c T Cells in Breast Cancer Patients
6 [+ ]* F5 x1 E/ V" eUsing Human DCs Engineered with Survivin mRNA . . . . . . . . . . . . . . . . . . . 275
' ]! ^, u; D- o4 EÖzcan Met and Inge Marie Svane' G: M( T9 ?. g# s; {  {" g
18 mRNA Electroporation as a Tool for Immunomonitoring . . . . . . . . . . . . . . . . 2938 I: Q' d- s1 K4 y8 I
Nathalie Cools, Kirsten Van Camp, Viggo Van Tendeloo, and Zwi Berneman1 l0 w- C* o( o7 K) Y. f, p! I/ }
19 mRNA PCR-Based Epitope Chase Method . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
. G7 r( Q6 C# a* M. HJean-Daniel Doucet, Dominique Gauchat, and Réjean Lapointe
' f9 f8 @" A& W7 P# D5 [Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321: e: R$ Q6 v8 z6 O/ J5 b7 d

# W1 v# Z  y$ ^1 I% h+ R4 E6 r) Z* a& U# t

dracula8988

顶顶顶

zpj589

give me to see

zpj589

骗人帖子，没有附件

电脑爱好者

能看到吗？

123456zsz

今天没事来逛逛  

txxxtyq

我起来了 哈哈 刚才迷了会  

txxxtyq

天啊. 很好的资源

我心飞翔

原来是这样  

dypnr

照你这么说真的有道理哦 呵呵 不进沙子馁~~~